Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05586243 · ClinicalTrials.gov registry record
Magnetic Resonance Spectroscopy Biomarkers IN Type 3 Gaucher Disease (GD3)
A clinical trial of Gaucher Disease, Type 3, sponsored by University of Minnesota.
- Recruiting
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT05586243: Recruiting study of Gaucher Disease, Type 3, sponsored by University of Minnesota.
NCT05586243 is a study of Gaucher Disease, Type 3 that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05586243, a study of Gaucher Disease, Type 3, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally, a secondary aim is to evaluate relationships between neurometabolites and disease parameters, such as genotype, enzyme levels and Gaucher disease (GD) biomarkers.
Primary Outcome
Characterize neurometabolite profiles of up to 18 metabolites including N-acetyl aspartate (a validated biomarker of neuronal integrity), glutamate and GABA (neurotransmitters), myo-inositol, glutamine, lactate and choline (inflammation biomarkers) and glutathione (anti-oxidant) in individuals with GD3.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2026-07-31 |
What NCT05586243 shows while recruiting
NCT05586243 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 1 condition, with Gaucher Disease, Type 3 appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT05586243 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05586243 about?
NCT05586243 is a clinical study titled "Magnetic Resonance Spectroscopy Biomarkers IN Type 3 Gaucher Disease (GD3)". Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well...
What is the current status of trial NCT05586243?
This trial is currently recruiting. The enrollment target is 5 participants. The study started on 2023-01-01. Estimated completion is 2026-07-31.
What conditions does trial NCT05586243 study?
This clinical trial studies the following conditions: Gaucher Disease, Type 3.
What interventions are being tested in trial NCT05586243?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05586243?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05586243 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease, Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI